Phase II study of Didemnin B in central nervous system tumors: A Southwest Oncology Group study

Investigational New Drugs

Volumn 16, Issue 4, 1998, Pages 331-332

  Taylor, Sarah A ^a   Giroux, Dorothy J ^b   Jaeckle, Kurt A ^c   Panella, Timothy J ^d   Dakhil, Shaker R ^e   Schold, S Clifford ^f  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b SW Oncology Group Statistical Center ^*  (United States)

^c UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^d THOMPSON CANCER SURVIVAL CENTER   (United States)

^e WICHITA COMMUNITY CLINICAL ONCOLOGY PROGRAM   (United States)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Central nervous system tumors; Didemnin B

Indexed keywords

DIDEMNIN B;

ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; BRAIN EDEMA; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG FATALITY; DRUG TOXICITY; DYSPNEA; FATIGUE; FEMALE; HEART INFARCTION; HUMAN; HYDROCEPHALUS; HYPERGLYCEMIA; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; LETHARGY; MALAISE; MALE; MUSCLE WEAKNESS; NAUSEA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RHABDOMYOLYSIS; VOMITING;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CENTRAL NERVOUS SYSTEM NEOPLASMS; DEPSIPEPTIDES; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDES, CYCLIC;

EID: 0032457858     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006273214056     Document Type: Article

References (3)

1. Annual Report to the Food and Drug Administration on Didemnin B (NSC-3253219, IND-245055), August 1996
2. Dorr FA, Kuhn JG, Phillips J, Von Hoff DD: Phase I clinical and pharmacokinetic investigation of Didemnin B, a cyclic depsipeptide. J Cancer Clin Oncol 24: 1699-1706, 1988
3. Stewart JA, Low JB, Roberts JD, Blow A: A phase I clinical trial of Didemnin B. Cancer 68: 2550-2554, 1991